Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 25, 2026, 4:22 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1201–1224 of 15,129 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Randomized Controlled Study Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess Intraocular Pressure and Ocular Safety of the Beta-3 Agonist Mirabegron in Research Subjects

NCT01284309
View directory record Official record
Conditions
Intraocular Pressure
Interventions
Mirabegron, Placebo
Drug
Lead sponsor
Astellas Pharma Inc
Industry
Eligibility
18 Years and older
Enrollment
321 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
2
States / cities
Tempe, Arizona • Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Dec 11, 2013 · Synced Oct 25, 2026, 4:22 PM EDT
Completed Phase 2 Interventional

A Dose-Range Study of Aleniglipron (GSBR-1290) in Participants Living With Obesity or Overweight With at Least One Weight-related Comorbidity

NCT06703021
View directory record Official record
Conditions
Obesity, Overweight, Chronic Weight Management
Interventions
aleniglipron or placebo
Drug
Lead sponsor
Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics
Industry
Eligibility
18 Years to 79 Years
Enrollment
85 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
10
States / cities
Glendale, California • Montclair, California • Valparaiso, Indiana + 7 more
Source: ClinicalTrials.gov public record
Updated Apr 28, 2026 · Synced Oct 25, 2026, 4:22 PM EDT
Completed Phase 3 Interventional Results available

Linagliptin as Add on Therapy to Empagliflozin 10 mg or 25 mg With Background Metformin in Patient With Type 2 Diabetes

NCT01778049
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
BI 10773, BI 10773 Placebo, BI 10773 / BI 1356, BI 10773 / BI 1356 Placebo
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
708 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
24
States / cities
Chino, California • Huntington Beach, California • San Diego, California + 20 more
Source: ClinicalTrials.gov public record
Updated Apr 4, 2016 · Synced Oct 25, 2026, 4:22 PM EDT
Completed Not applicable Interventional

Double Arm Pivotal Study to Evaluate the Neurolyser XR for the Treatment of Chronic Low Back Pain

NCT05154448
View directory record Official record
Conditions
Facet Syndrome of Lumbar Spine
Interventions
Non-Invasive Thermal Ablation of the Medial Branch Nerves (Neurolyser XR), Sham procedure
Device · Other
Lead sponsor
FUSMobile Inc.
Industry
Eligibility
50 Years to 85 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
10
States / cities
Stamford, Connecticut • Jacksonville, Florida • Miami, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Feb 7, 2025 · Synced Oct 25, 2026, 4:22 PM EDT
Completed Phase 3 Interventional

A Study of RO4917838 (Bitopertin) in Patients With Sub-optimally Controlled Symptoms of Schizophrenia (WN25306)

NCT01235585
View directory record Official record
Conditions
Schizophrenia
Interventions
Placebo, bitopertin [RO4917838]
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
597 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
25
States / cities
Carson, California • Garden Grove, California • Long Beach, California + 19 more
Source: ClinicalTrials.gov public record
Updated Nov 2, 2016 · Synced Oct 25, 2026, 4:22 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Assess the Safety, Tolerability and Pharmacokinetics of Single Ascending Oral Doses of J147

NCT03838185
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
J147, Placebo
Drug
Lead sponsor
Abrexa Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 85 Years
Enrollment
64 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Sep 3, 2020 · Synced Oct 25, 2026, 4:22 PM EDT
Terminated Phase 2 Interventional Results available

A Study to Evaluate the Efficacy and Safety of GSK3915393 in Participants With Idiopathic Pulmonary Fibrosis (IPF)

NCT06317285
View directory record Official record
Conditions
Idiopathic Pulmonary Fibrosis
Interventions
GSK3915393, Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
158 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
10
States / cities
Newport Beach, California • Jacksonville, Florida • St. Petersburg, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Sep 18, 2026 · Synced Oct 25, 2026, 4:22 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Safety and Immunogenicity of V116 in Pneumococcal Vaccine-naïve Adults (V116-003, STRIDE-3)

NCT05425732
View directory record Official record
Conditions
Pneumococcal Infection
Interventions
V116, PCV20
Biological
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
2,663 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
60
States / cities
Birmingham, Alabama • Glendale, Arizona • Mesa, Arizona + 52 more
Source: ClinicalTrials.gov public record
Updated Oct 26, 2024 · Synced Oct 25, 2026, 4:22 PM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate the Safety, Tolerability, Efficacy, Pharmacokinetics and Pharmacodynamics of M281 Administered to Adults With Generalized Myasthenia Gravis

NCT03772587
View directory record Official record
Conditions
Generalized Myasthenia Gravis
Interventions
M281, Placebo
Drug · Other
Lead sponsor
Momenta Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
31
States / cities
Phoenix, Arizona • Tucson, Arizona • Los Angeles, California + 26 more
Source: ClinicalTrials.gov public record
Updated Jun 27, 2023 · Synced Oct 25, 2026, 4:22 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Safety, Tolerability, and Efficacy of MTP-131 for the Treatment of Mitochondrial Myopathy

NCT02367014
View directory record Official record
Conditions
Mitochondrial Myopathy
Interventions
elamipretide (low dose), elamipretide (intermediate dose), elamipretide (high dose), Placebo
Drug
Lead sponsor
Stealth BioTherapeutics Inc.
Industry
Eligibility
16 Years to 65 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
4
States / cities
San Diego, California • Boston, Massachusetts • Akron, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 27, 2019 · Synced Oct 25, 2026, 4:22 PM EDT
Withdrawn Phase 3 Interventional

Continuous Infusion of Ropivacaine Hydrochloride in Reducing Pain After Surgery in Patients With Bladder Cancer

NCT02438852
View directory record Official record
Conditions
Bladder Carcinoma, Post-operative Pain
Interventions
Placebo, Questionnaire Administration, Ropivacaine Hydrochloride
Other · Drug
Lead sponsor
University of Southern California
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Apr 16, 2019 · Synced Oct 25, 2026, 4:22 PM EDT
Terminated Phase 2 Interventional

Efficacy and Safety Study of TOLAMBA™ in Ragweed-Allergic Adults

NCT00387738
View directory record Official record
Conditions
Rhinitis, Allergic, Seasonal
Interventions
Amb a 1 immunostimulatory oligodeoxyribonucleotide conjugate, Histamine base
Biological
Lead sponsor
Dynavax Technologies Corporation
Industry
Eligibility
18 Years to 55 Years
Enrollment
738 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
28
States / cities
Oxford, Alabama • Stockbridge, Georgia • Normal, Illinois + 22 more
Source: ClinicalTrials.gov public record
Updated Apr 16, 2019 · Synced Oct 25, 2026, 4:22 PM EDT
Completed Phase 3 Interventional Results available

A Study to Find Out if Fezolinetant Helps Reduce Moderate to Severe Hot Flashes in Women Going Through Menopause

NCT04003155
View directory record Official record
Conditions
Hot Flashes
Interventions
fezolinetant, placebo
Drug
Lead sponsor
Astellas Pharma Global Development, Inc.
Industry
Eligibility
40 Years to 65 Years · Female only
Enrollment
527 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
72
States / cities
Andalusia, Alabama • Birmingham, Alabama • Ensley, Alabama + 62 more
Source: ClinicalTrials.gov public record
Updated Nov 4, 2024 · Synced Oct 25, 2026, 4:22 PM EDT
Completed Phase 3 Interventional

EPIC(Effect of PhosLo on Phosphorus Levels in Chronic Kidney Disease)

NCT00211978
View directory record Official record
Conditions
Hyperphosphatemia, Kidney Failure
Interventions
calcium acetate, placebo
Drug
Lead sponsor
Nabi Biopharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jan 8, 2008 · Synced Oct 25, 2026, 4:22 PM EDT
Completed Phase 1 Interventional

Study of the Fecal Microbiome in Patients With Parkinson's Disease

NCT03671785
View directory record Official record
Conditions
Parkinson Disease
Interventions
PRIM-DJ2727, Placebo oral capsule
Drug
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
55 Years to 75 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 24, 2023 · Synced Oct 25, 2026, 4:22 PM EDT
Completed Phase 1 Interventional

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of (PEG)-BHD1028

NCT06563115
View directory record Official record
Conditions
Insulin Resistance
Interventions
(PEG)-BHD1028 Single Ascending Dose, (PEG)-BHD1028 Multiple Ascending Dose, Placebo
Drug · Other
Lead sponsor
EncuraGen, Inc
Industry
Eligibility
18 Years to 75 Years
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Aug 20, 2024 · Synced Oct 25, 2026, 4:22 PM EDT
Recruiting Phase 3 Interventional

Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis (TETON-PPF)

NCT05943535
View directory record Official record
Conditions
Progressive Pulmonary Fibrosis, Interstitial Lung Disease
Interventions
Placebo, Inhaled Treprostinil, Treprostinil Ultrasonic Nebulizer
Drug · Device
Lead sponsor
United Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
698 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
74
States / cities
Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 60 more
Source: ClinicalTrials.gov public record
Updated Jul 13, 2026 · Synced Oct 25, 2026, 4:22 PM EDT
Completed Phase 2 Interventional Results available

Riociguat in Scleroderma Associated Digital Ulcers

NCT02915835
View directory record Official record
Conditions
Scleroderma, Digital Ulcers
Interventions
Riociguat, Placebo
Drug
Lead sponsor
Dinesh Khanna, MD, MS
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
5
States / cities
Washington D.C., District of Columbia • Ann Arbor, Michigan • New York, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 24, 2019 · Synced Oct 25, 2026, 4:22 PM EDT
Completed Phase 2 Interventional Results available

CM-101 in PSC Patients -The SPRING Study

NCT04595825
View directory record Official record
Conditions
Primary Sclerosing Cholangitis
Interventions
Anti-human CCL24 monoclonal antibody (CM-101), Placebo
Biological · Other
Lead sponsor
ChemomAb Ltd.
Industry
Eligibility
18 Years to 75 Years
Enrollment
77 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
8
States / cities
La Jolla, California • Sacramento, California • Chicago, Illinois + 4 more
Source: ClinicalTrials.gov public record
Updated Jul 2, 2026 · Synced Oct 25, 2026, 4:22 PM EDT
Completed Phase 3 Interventional Results available

Study Of Adults And Adolescents With Vasomotor Rhinitis

NCT00117325
View directory record Official record
Conditions
Rhinitis, Vasomotor
Interventions
GW685698X
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
12 Years and older
Enrollment
352 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
38
States / cities
Beverly Hills, California • Huntington Beach, California • Mission Viejo, California + 34 more
Source: ClinicalTrials.gov public record
Updated Mar 13, 2018 · Synced Oct 25, 2026, 4:22 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Singe Dose Study of PF- 06946860 in Healthy Adult Japanese Participants

NCT03974776
View directory record Official record
Conditions
Healthy
Interventions
PF-06946860, Placebo
Biological · Other
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Anaheim, California
Source: ClinicalTrials.gov public record
Updated Jan 29, 2020 · Synced Oct 25, 2026, 4:22 PM EDT
Completed Phase 3 Interventional Results available

Study to Evaluate Efficacy and Safety of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) Regimen Versus Boosted Protease Inhibitor (bPI) Along With Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF) Regimen in Virologically-Suppressed, HIV-1 Infected Participants

NCT02269917
View directory record Official record
Conditions
Human Immunodeficiency Virus Type 1
Interventions
D/C/F/TAF, Boosted Protease Inhibitor (bPI), FTC/TDF
Drug
Lead sponsor
Janssen R&D Ireland
Industry
Eligibility
18 Years and older
Enrollment
1,149 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
38
States / cities
Phoenix, Arizona • Bakersfield, California • Beverly Hills, California + 35 more
Source: ClinicalTrials.gov public record
Updated Dec 9, 2021 · Synced Oct 25, 2026, 4:22 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Naldemedine in Treating Opioid-induced Constipation

NCT01993940
View directory record Official record
Conditions
Opioid-induced Constipation
Interventions
Naldemedine, Placebo
Drug
Lead sponsor
Shionogi
Industry
Eligibility
18 Years to 80 Years
Enrollment
553 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
49
States / cities
Birmingham, Alabama • Homewood, Alabama • Goodyear, Arizona + 46 more
Source: ClinicalTrials.gov public record
Updated May 30, 2017 · Synced Oct 25, 2026, 4:22 PM EDT
Recruiting Phase 2 Interventional

A Study to Evaluate the Use of Resmetirom in Participants With MASLD and HIV

NCT07143968
View directory record Official record
Conditions
MASLD - Metabolic Dysfunction-Associated Steatotic Liver Disease, HIV (Human Immunodeficiency Virus)
Interventions
Resmetirom, Placebo Control
Drug
Lead sponsor
Naga P. Chalasani
Other
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
10
States / cities
Birmingham, Alabama • La Jolla, California • San Francisco, California + 7 more
Source: ClinicalTrials.gov public record
Updated Jul 30, 2026 · Synced Oct 25, 2026, 4:22 PM EDT